UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Anebulo Pharmaceuticals Inc (ANEB)

Anebulo Pharmaceuticals Inc (ANEB)
0.5700 x 1 1.6800 x 2
Post-market by (Cboe BZX)
1.0200 -0.0600 (-5.56%) 04/04/25 [NASDAQ]
0.5700 x 1 1.6800 x 2
Post-market 1.0200 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0000
Day High
1.0700
Open 1.0500
Previous Close 1.0800 1.0800
Volume 37,200 37,200
Avg Vol 55,085 55,085
Stochastic %K 2.37% 2.37%
Weighted Alpha -82.04 -82.04
5-Day Change -0.3400 (-25.00%) -0.3400 (-25.00%)
52-Week Range 0.8001 - 3.3000 0.8001 - 3.3000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,907
  • Shares Outstanding, K 41,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,200 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta -1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +1,665,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9078 +12.36%
on 03/07/25
Period Open: 1.0500
2.1900 -53.42%
on 03/19/25
-0.0300 (-2.86%)
since 03/04/25
3-Month
0.9078 +12.36%
on 03/07/25
Period Open: 1.6500
2.1900 -53.42%
on 03/19/25
-0.6300 (-38.18%)
since 01/03/25
52-Week
0.8001 +27.48%
on 12/20/24
Period Open: 2.9100
3.3000 -69.09%
on 04/18/24
-1.8900 (-64.95%)
since 04/04/24

Most Recent Stories

More News
Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

ANEB : 1.0200 (-5.56%)
Ligand Reports First Quarter 2023 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management...

LGND : 99.57 (-3.43%)
TVTX : 14.99 (-9.48%)
VKTX : 22.62 (-6.61%)
NOVN : 0.0941 (-24.84%)
NVS : 105.85 (-5.71%)
ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel...

ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company”...

ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (“ACI”) and substance addiction...

ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company”...

ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder...

ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction...

ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction...

ANEB : 1.0200 (-5.56%)
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder...

ANEB : 1.0200 (-5.56%)

Business Summary

Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 1.1300
2nd Resistance Point 1.1000
1st Resistance Point 1.0600
Last Price 1.0200
1st Support Level 0.9900
2nd Support Level 0.9600
3rd Support Level 0.9200

See More

52-Week High 3.3000
Fibonacci 61.8% 2.3450
Fibonacci 50% 2.0501
Fibonacci 38.2% 1.7551
Last Price 1.0200
52-Week Low 0.8001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades